Mad Money host Jim Cramer dissects how Wall Street digested earnings reports by Buffalo Wild Wings and Panera Bread.» Read More
After earnings Panera marched higher while Buffalo Wild Wings tanked by 15 percent. That doesn’t seem right.
Jim Cramer can’t help but wonder if this old dog of a stock has learned new tricks.
Are you finding it next to impossible to anticipate this market? There’s a reason. In fact, Cramer says there are five of them.
Mobileye is set to go public next week. CNBC's Phil LeBeau provides insight into the software maker for driverless cars.
The Fast Money traders take a look at today's biggest market movers.
With the dollar hitting 10-month highs today, Paul Hickey, Bespoke Investment Group, says to focus on companies with domestic exposure.
Behrooz Abdi, InvenSense CEO and president, discusses a strong growth forecast for the year and expresses excitement about market share gains. But he doesn't talk about the company's relationship with Apple.
CNBC's Bertha Coombs reports Carl Icahn now holds just a 3.61 percent stake in Family Dollar.
The FM traders break down trades on Weight Watchers and Shutterfly following their earnings reports.
CNBC's Kate Kelly reports the S&P has declared Argentina is in the state of selective default. The Argentina Economy Prime Minister is expected to speak.
Neil Doshi, CRT Capital, analyzes Q2 earnings by Yelp.
Dissecting quarterly numbers by social stocks, with the Fast Money traders.
Marc Harris, RBC Capital Markets Head of Global Research, discusses his investment strategy and provides his top three stock picks for the second half.
One company reported a strong quarter and the other flopped—but CNBC's Jim Cramer thinks both stocks are a buy.
CNBC's Jim Cramer on Wednesday identified two biotechnology stocks that he thinks could climb.
CNBC's Jim Cramer explains why he is watching Pitney Bowes and Eaton Corporation.
Shares of Twitter are surging and nearing its best day since its IPO day. Insight, with the "Squawk on the Street" crew.
Jim Cramer explains how a cholesterol drug breakthrough at Regeneron could drive the stock higher.
On Tuesday, investors gave earnings from International Paper a Bronx cheer, with shares declining about 1.5 percent after the release.
Shares came public at $16. By the second day of trade they leapt to $34. What does Cramer make of the price action?